Mustang was founded by Fortress Biotech, Inc. The company operates a licensing and partnership model, acquiring rights to cell and gene therapy technologies and advancing them through clinical development. As of June 2, 2026, Mustang Bio has a market capitalization of $5.77 million, reflecting significant shareholder dilution from its peak, though the company continues advancing multiple clinical programs.
Cyborg Score Rationale
Since August 2017, Mustang Bio's market cap has decreased from $257.00M to $5.77M, a decrease of 97.75%. The company is pre-revenue and operating with limited capital resources in a highly competitive cell therapy space where clinical and regulatory risks are substantial.
Top Insights
Dramatic market cap erosion of 97.75% since 2017 suggests persistent execution challenges or investor skepticism about the pipeline
Lead program MB-106 targets large oncology markets (non-Hodgkin lymphoma, chronic lymphocytic leukemia) with Phase I status; regulatory path remains unclear
Partnerships with Nationwide Children's Hospital, Mayo Clinic, and academic institutions provide validation but do not guarantee clinical success
Current market cap of $5.77M as of June 2, 2026 indicates severe capital constraint risk and potential dilution from future financing needs
Named Competitors
Kymriah — FDA-approved CAR-T therapy for B-cell acute lymphoblastic leukemia and lymphoma
Yescarta — Leading commercial CAR-T platform for relapsed/refractory large B-cell lymphoma
Juno CAR-T — CAR-T therapy development and commercialization